The Next Acetaminophen Tablet You Take Could Be Made From PET
Jun 27, 2025 8:53 AM This research could represent the first documented case of acetaminophen production from plastic waste using E. coli bacteria. acetaminophen pill box, boxpaper, blister tablets Photograph: Jorge Martinez
Researchers at the University of Edinburgh have succeeded in transforming certain plastic waste into acetaminophen using the natural properties of the common bacterium Escherichia coli ( E. coli ). This breakthrough represents a milestone with the potential to drive more sustainable methods of drug production and, at the same time, contribute to the reduction of plastic pollution globally.
The study, led by Stephen Wallace, revealed that E. coli cells contain phosphate, an organic compound capable of catalyzing a chemical reaction known as Lossen rearrangement. In general terms, this process involves the rearrangement of the atoms of a hydroxamate ester molecule to form a new structure called isocyanate, a chemical intermediate that, when reacted with water, produces primary amines. These substances are essential in numerous biological processes and in drug synthesis.
Using synthetic biology, the scientists manipulated the bacteria to redirect their internal chemistry and transform a PET-derived molecule known as terephthalic acid into the active ingredient in acetaminophen. They used a fermentation process, similar to that used in brewing beer, to accelerate the conversion of industrial PET waste into the drug, obtaining results in less than 24 hours. According to the findings, approximately 90 percent of the final product corresponded to acetaminophen.
Importantly, this conversion was done at room temperature and with virtually no carbon emissions, suggesting that the drug can be produced in a more environmentally friendly way.
Wallace noted that what was most surprising about the process was that the Lossen rearrangement occurred naturally within living bacteria, without the need for laboratory catalysts. That is, they took advantage of the microbial cells' own capabilities to trigger the desired reaction.
'The funny thing is that we didn't have to teach the bacteria how to do the reaction: The trick was to realize that they already had the tools, and we just had to guide them,' explained the researcher in statements reported by El País. 'We used synthetic biology to build new metabolic pathways within the bacteria that guide their chemistry toward producing the compound we wanted. In this case, a drug.' Sustainable Drug Production
The work, published in the journal Nature, could be the first documented case of acetaminophen production from plastic waste using E. coli . However, the authors stress that further studies will be necessary to achieve industrial-scale production. In addition, they caution that the safety and efficacy of the resulting drug in humans have yet to be evaluated, so future research will be required.
Despite these limitations, the scientists emphasize that their results open up new possibilities for addressing the problem of plastic waste and reducing greenhouse gas emissions associated with drug manufacturing.
Currently, the production of drugs such as acetaminophen consumes thousands of tons of fossil fuels, especially petroleum, which contributes significantly to climate change. In turn, PET generates more than 350 million tons of waste per year, causing serious damage to the environment. Although this material is recyclable, current methods often result in products that perpetuate global plastic pollution.
'This work demonstrates that PET plastic is not just a waste product or a material destined to become more plastic: Microorganisms can transform it into valuable new products, including those with therapeutic potential,' concluded Wallace.
This story originally appeared on WIRED en Español and has been translated from Spanish.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Voices: Putting cancer warnings on alcohol would help me drink less
Back in the early noughties, the indoor smoking ban led to an outcry over 'the nanny state'. The same happened when cigarette advertising was banned, and when manufacturers were required to plaster packs with images of diseased lungs. Yet over the past 40 years, according to Cancer Research, lung cancer rates in men have dropped by around 60 per cent. We may think we crave the rugged freedoms of the Marlboro Man, but given the facts, it turns out we don't actually want to die. And yet when it comes to alcohol, one of the world's biggest killers, a key driver of cancers, heart disease, strokes and obesity, there are no images of rotting livers on the chilled Sauvignon. The presentation of booze in the supermarket aisles is as benign as kitchen roll and chicken pie. It's described on restaurant menus with biblical reverence, it's advertised on TV in a hazy, golden-hour glow, and every other greetings card carries a hilarious reference to the booze-addled nature of the recipient. It is both normalised and celebrated, despite being the fifth greatest risk factor for death in the UK. Now, a group of major medical and health organisations have signed a letter to the Prime Minister calling for alcohol to carry explicit warnings that its consumption can cause cancer. The World Cancer Research Fund, which spearheaded the letter, cited 'shockingly low' public awareness that alcohol raises the risk of seven types of cancer – these being breast, bowel, stomach, head, neck, liver and mouth – and insisted that 'bold and unambiguous labelling' is urgently need to help save lives. Token efforts have long been made by the industry to toe a wavering line of responsibility – the number of units a bottle of wine contains written in a font the size of a gnat's IKEA instructions, or a glancing mention that pregnant women shouldn't drink. According to the Advertising Standards Authority, 'Lively, but responsible, social interaction or party scenes with alcohol present are allowed but…no behaviour may be adolescent or childish.' If only that diktat held true in real-life 'party scenes.' Initially, like much of Gen X and our wine-necking Boomer parents, I was resistant to the idea of cancer warnings. If I wanted to slowly kill myself in a responsible and socially acceptable manner, I felt it should be my choice to do so. But after another night of drinking slightly too much with friends, waking bathed in shame and a light prosecco sweat, I reconsidered. Women, particularly, are at risk of harm from alcohol, simply because we're smaller. If every time I picked up the wine bottle to top up my glass – over a healthy dinner! So civilised! – it reminded me that I was increasing my risk of cancer, I suspect I might put it back down. Humans like to ignore the dangers when it's something we want to do until it becomes impossible to turn a blind eye. But this time, it's not so much the consumers resisting warnings as the enormously powerful drinks industry. It's already up against Gen Z's wellbeing crusade, with a tsunami of kumbucha and kefir washing away the old-school shots and spirits from nights out. The risk of drinkers murmuring, 'Actually, I don't think I do want seven types of cancer' and switching the kettle on instead is a step too far. A spokesperson for the Portman Group, which oversees UK alcohol labelling in the UK, says: 'Whilst we do not dispute the link between alcohol and certain cancers… blanket cancer warning labels…can create unnecessary anxiety, eroding trust in health advice and alienating the very people who require support.' As an argument, this is weaker than a sixth-form debating point scribbled on the bus. Imagine the motor industry saying, 'Road signs create unnecessary anxiety. Let's not warn people that they might crash, lest we alienate drivers.' The spokesperson added that most alcohol products already include advice to limit drinking to 14 units a week, and claimed that 'most people drink within guidelines.' According to NHS Digital, however, 24 per cent of Brits drink more than this, while the charity Drinkaware has found that 32 per cent of men and 15 per cent of women regularly sink more than the recommended limit – and it is a limit, not a target. Doctors repeatedly warn that there is no safe level of alcohol consumption, and in April, the World Health Organisation advised that women should drink no alcohol at all to avoid a heightened risk of breast cancer. I'm aware that even reading this is annoying. I share the general British resentment over finger-wagging admonishments from the Fun Police. I want to say, 'You'll prise my Picpoul from my cold, dead hand.' The only thing is, I'd rather not be cold and dead – and I'm increasingly convinced that warning labels can only be a good thing. Although, of course, we must be careful how we approach this new regime. After all, we wouldn't want to alienate anybody.
Yahoo
3 hours ago
- Yahoo
Plans unveiled for NHS funding to be linked to patient feedback
NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."
Yahoo
4 hours ago
- Yahoo
Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP
With profound change in sight for the UK's National Health Service (NHS), a new report indicates that a technology-driven vision for the national health system could add £40bn ($54.8bn) to the nation's annual GDP. Co-authored by Boston Consulting Group (BCG), Siemens Healthineers, and Imperial College London, the report follows the UK Spending Review on 11 June, in which Chancellor of the Exchequer Rachel Reeves announced that the NHS will receive a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current levels over the next three years to reach £226bn by 2029. Reeves also revealed that the funding would increase the NHS's technology budget by almost 50%, with £10bn ($13.5bn) of the total funding earmarked to bring the 'analogue health system into the digital age'. Commissioned by the NHS as input to its 10-Year Plan, which is anticipated to be released in early July, the report foresees that innovation in diagnosis has the potential to impact population outcomes through risk stratification and intervention to 'prevent disease and alleviate burden on the broader healthcare system'. According to the research, by addressing health inequalities through predictive, personalised and preventative care, two to three million healthy life years could be added to the five most economically deprived groups among the UK population each year, thereby boosting the UK's GDP by around £40bn each year. Achieving this aim would primarily be driven by implementing technologies such as AI for the early diagnosis of diseases such as cancer, the report stated. Also, the report envisions the deployment of AI and technologies including remote patient monitoring tools, to take preventative action on conditions such as high blood pressure and hypertension that are well-established predicates of life-threatening conditions such as coronary artery disease (CAD), stroke, and cancer. In turn, the report forecasts that the impact of technologies' deployment in the NHS would deliver £12bn-£18bn ($16.4-$24.7bn) in productivity gains for NHS healthcare systems annually. By integrating diagnostic data into NHS R&D, the report also forecasts that drug development timelines could be reduced, resulting in new drugs being brought to patients up to twice as fast, with operational cost savings and commercial data revenue worth £10bn-£15bn ($13.7bn- $20.5bn) to the NHS annually. Ben Horner, managing director and partner at BCG and co-author of the report, said: 'As the UK Government prepares to set out its 10-Year Health Plan, this research highlights the scale of the opportunity ahead. 'By embracing technology and data-driven innovation, the NHS could add over £40bn to UK GDP annually. This would improve patient outcomes, easing pressure on frontline services and boosting productivity across the system. The foundations are already in place; now is the moment to shift from pilots to full-scale implementation.' "Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
